Gaxos to Participate in Upcoming Devcom and Gamescom Conferences on August 18th to 25th in Cologne, Germany
Newsfilter· 2024-08-07 20:30
Roseland, NJ, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various sectors, today announced that it will participate in the upcoming Devcom Developer Conference on August 18th - Aug 20th and Gamescom Conference on August 21st – 25th in Cologne, Germany. "We are excited to be part of Devcom and Gamescom this year," said Vadim Mats, CEO of Gaxos. "These conferences provide us with a fantastic opportunity to engage ...
SKYX Announces Corporate Update Call
Newsfilter· 2024-08-07 20:30
文章核心观点 - 公司SKYX是一家拥有97项美国和全球专利的智能平台技术公司,致力于让家庭和建筑物变得更加安全、智能和先进 [1][4] - 公司将于2024年8月12日举行第二季度财报电话会议,公司高管将参与其中 [1][2] - 公司拥有60多个照明和家居装饰网站,覆盖零售和商业两个细分市场 [4] - 公司的技术强调高质量和易用性,同时显著提升家庭和建筑物的安全性和生活方式 [4] - 公司认为其产品是美国和全球家庭及其他建筑物中每个房间的必需品 [4] 公司概况 - 公司成立于美国,在纳斯达克上市,股票代码为SKYX [1] - 公司拥有97项美国和全球专利和专利申请 [1][4] - 公司的使命是让家庭和建筑物变得更加安全、智能和先进,成为新的标准 [4] 财务信息 - 公司将于2024年8月12日发布第二季度财务业绩 [1][2] - 公司需要持续筹集资金以支持业务运营,这可能无法以可接受的条款获得 [5][6] - 公司存在持续经营的不确定性 [6] 发展战略 - 公司努力推动其产品和技术成为标准配置,包括在家庭、酒店、办公室和邮轮上使用 [5][6] - 公司正在寻求销售、许可或其他战略机会 [6] - 公司正在努力吸引和留住关键高管和合格人才 [6]
Vericel to Present at the Canaccord Genuity Growth Conference on Wednesday, August 14, 2024
Newsfilter· 2024-08-07 20:30
文章核心观点 - 公司是先进疗法领域的领导者,专注于运动医学和严重烧伤护理市场 [1][3] - 公司通过生物学创新和医疗技术相结合,拥有高度差异化的创新细胞疗法和专业生物制品组合,可修复伤害并恢复生命 [3] - 公司在美国销售三种产品:MACI、Epicel和NexoBrid [3] 公司概况 - 公司名称为Vericel Corporation,总部位于马萨诸塞州剑桥 [1] - 公司股票代码为NASDAQ:VCEL [1] - 公司CEO为Nick Colangelo [1] - 公司将于2024年8月14日在Canaccord Genuity Growth Conference上进行演讲 [1][2] 产品介绍 - MACI是一种自体细胞化支架产品,用于修复成人膝盖单一或多发全层软骨缺损 [3] - Epicel是一种永久性皮肤替代品,用于治疗体表面积大于或等于30%的重度皮肤烧伤患者 [3] - NexoBrid是一种生物孤儿产品,含有蛋白酶,用于成人深部部分厚度和/或全厚度烧伤的烧伤组织清除 [3]
Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights
Newsfilter· 2024-08-07 20:23
Survival analyses with CNM-Au8® 30 mg treatment compared to matched PRO-ACT controls demonstrated improved survival up to 3.5 years post-baseline CNM-Au8 treated participants in the HEALEY ALS Platform Trial with substantial neurofilament light (NfL) declines (CNM-Au8 NfL Responders) demonstrated significant clinical improvements in survival, functional status (slowed ALSFRS-R decline), and combined function and survival (CAFS scores) compared to NfL non-responders CNM-Au8 demonstrated neuroprotective effec ...
Greystone Housing Impact Investors Reports Second Quarter 2024 Financial Results
Newsfilter· 2024-08-07 20:15
OMAHA, Neb., Aug. 07, 2024 (GLOBE NEWSWIRE) -- On August 7, 2024, Greystone Housing Impact Investors LP (NYSE: GHI) (the "Partnership") announced financial results for the three months ended June 30, 2024. Financial Highlights The Partnership reported the following results as of and for the three months ended June 30, 2024: Net income of $0.19 per Beneficial Unit Certificate ("BUC"), basic and diluted Cash Available for Distribution ("CAD") of $0.27 per BUC Total assets of $1.53 billion Total Mortgage Reven ...
STRATA Skin Sciences to Report Second Quarter 2024 Financial Results on August 14, 2024 and Provide Corporate Update
Newsfilter· 2024-08-07 20:15
HORSHAM, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report second quarter 2024 financial results on Wednesday, August 14, 2024 after the market close. STRATA management will host a conference call at 4:30 p.m. ET on Wednesday, August 14, 2024 to review financial results ...
Clarivate to Present at the Oppenheimer 27th Annual Technology, Internet & Communications Virtual Conference on August 12
Prnewswire· 2024-08-07 20:15
文章核心观点 - 公司宣布首席财务官将在即将举行的Oppenheimer年度科技、互联网和通信会议上发表演讲 [1] - 公司是一家全球领先的转型情报提供商,提供丰富的数据、见解和分析、工作流解决方案以及专业服务 [2] 公司概况 - 公司在学术与政府、知识产权以及生命科学与医疗保健领域提供服务 [2] 会议信息 - 公司首席财务官将于2024年8月12日下午2:55在Oppenheimer年度科技、互联网和通信虚拟会议上发表演讲 [1] - 演讲将通过网络直播的方式进行,并将提供回放 [1]
Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide
Newsfilter· 2024-08-07 20:13
Silo to advance homing peptide development for initial indication in multiple sclerosis SARASOTA, FL, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered into an agreement with WuXi AppTec (Hong Kong) Limited, a leading global contract research organization (CRO) ...
Generating a Brighter Future for Renewable Energy in Arkansas
Prnewswire· 2024-08-07 20:07
文章核心观点 - NorthStar Clean Energy和通用汽车(GM)共同推出了Newport Solar项目,这是一个180MW的可再生能源项目,旨在为GM在密西西比独立系统运营商(MISO)地区的部分工厂提供可再生电力[2] - 该项目是NorthStar Clean Energy和GM之间不断创新和合作的成果,是GM实现其全球范围内减少范围2温室气体排放的关键举措之一[6] - 该项目预计每年可产生约41万兆瓦时的可再生能源,相当于为3万多个阿肯色州家庭提供电力[7] - 根据15年的可再生能源购买协议,该新设施产生的可再生能源证书相当于种植近500万棵树[8] 公司相关 - NorthStar Clean Energy是一家总部位于密歇根州的可再生能源公司,拥有和运营超过1500兆瓦的发电能力,包括密歇根、威斯康星和俄亥俄州的太阳能装置,德克萨斯州和俄亥俄州的风电资产,密歇根州的天然气和热电联产设施,以及密歇根州和北卡罗来纳州的生物质发电厂[9] - NorthStar Clean Energy计划将其唯一的燃煤电厂改造为一座60兆瓦的生物质发电厂,并配备二氧化碳捕集和储存(BECCS)技术,这将是美国首批BECCS项目之一[9] 行业相关 - 该项目是NorthStar Clean Energy和GM之间不断创新和合作的成果,体现了双方在可再生能源和可持续发展方面的共同承诺[4][5] - 该项目有助于GM实现其全球范围内减少范围2温室气体排放的目标,包括提高能源效率、采购可再生电力、使用更可靠的电力、增强供应可靠性,以及在不断扩大的可再生能源合作伙伴网络中进行重大全球投资[6]
Better Choice Company Announces Formation of Special Committee to Evaluate M&A and Asset Monetization
Newsfilter· 2024-08-07 20:05
TAMPA, Fla., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Better Choice Company Inc. (NYSE:BTTR) ("Better Choice" or "the Company"), a pet health and wellness company, today announced that its Board of Directors has formed a special committee consisting of Lionel Conacher, John Word III and Michael Young. The committee's mandate will be to evaluate all and any M&A and asset monetization opportunities, including joint ventures, acquisitions, dispositions, and may re-engage certain candidates previously expressing an in ...